Hepatitis B Community
GlobeImmune annouced GS-4774 (GI-13020) into Phase 2
About This Community:

This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

GlobeImmune annouced GS-4774 (GI-13020) into Phase 2

GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) in Patients with Chronic Hepatitis B Virus Infection


(Thomson Reuters ONE via COMTEX) -- LOUISVILLE, Colo., October 15, 2013 - GlobeImmune, Inc., today announced that it has earned a milestone payment from Gilead Sciences, Inc. under the terms of an exclusive worldwide license and collaboration agreement established in 2011 for the development and commercialization of Tarmogen products® for use in conjunction with Viread® (tenofovir disoproxil fumarate) and other oral therapies for the treatment of chronic hepatitis B virus (HBV) infection.

The milestone payment is based on the initiation of a Phase 2 clinical trial investigating GS-4774 (formerly GI-13020) in patients with chronic hepatitis B virus (HBV) infection. The GS-4774 Tarmogen, consists of whole, heat-killed, recombinant S. cerevisiae yeast genetically modified to express HBV antigens.

The Phase 2 clinical trial will enroll patients in a randomized, open-label trial evaluating different doses of GS-4774 in virally-suppressed patients. In addition to continuing ongoing oral antiviral treatment, patients will be treated with GS-4774 administered once per month. The primary endpoint for this trial is decline in serum HBV surface antigen (HBsAg). Surface antigen seroconversion defines a cure in chronically infected patients.

"GS-4774 demonstrated a favorable safety and immunogenicity profile in a previous Phase 1 clinical trial, which paved the way for the initiation of this Phase 2 study," said Timothy C. Rodell, M.D., Chief Executive Officer at GlobeImmune. "We believe that the antigen-specific immune response against HBV driven by GS-4774 may improve rates of seroconversion in patients already being treated with antiviral therapy."

HBV infection is the most common form of chronic viral hepatitis in the world. Approximately 350 million people worldwide are chronic carriers of HBV, resulting in more than 620,000 deaths annually from liver-related diseases. In the United States, chronic HBV infection affects up to 1.4 million people. Current treatment for HBV includes once-daily oral antiviral therapy medicines to suppress virus replication. These antiviral products have been effective in controlling the disease but generally do not result in a long-term cure, thus requiring chronic suppressive therapy.

For more information on the trial, please visit http://www.clinicaltrials.gov/.
Tags: GS-4774
Avatar_m_tn
Thanks for this information and hope this drug candidate will pass to phase III in near future.
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
veteranB
CA
9624973_tn?1413019730
Blank
melcul
United Kingdom
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
mike9111
MI
Avatar_m_tn
Blank
SafiSifa
Izmir, Turkey